XML 50 R41.htm IDEA: XBRL DOCUMENT
v3.23.3

Subsequent Events (Details) - License agreement $ in Millions | 1 Months Ended |
--- | --- | ---
Oct. 31, 2023 USD ($) | Oct. 04, 2023 USD ($) item
Underwritten public offering |  |
Subsequent Events |  |
Maximum number of indications under regulatory approval and commercial sales milestones | item |  | 3
Subsequent Event |  |
Subsequent Events |  |
Upfront license fee paid | $ 15.0 |
License fee payable in milestone |  | $ 305.0
License fee payable related to clinical development milestones | $ 20.0 |
Maximum number of indications under clinical development milestones | item |  | 70,000,000
License fee payable related to regulatory approval and commercial sales milestones |  | $ 215.0

X
- Definition The amount of license fee payable in milestones. + References No definition available. + Details
Name: | atxs_LicenseeFeePayable
Namespace Prefix: | atxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of indications for license fee payable related to clinical development milestones. + References No definition available. + Details
Name: | atxs_LicenseeFeePayableClinicalDevelopmentMilestonesMaximumNumberOfIndications
Namespace Prefix: | atxs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of maximum license fee payable related to clinical development milestones. + References No definition available. + Details
Name: | atxs_LicenseeFeePayableMaximumClinicalDevelopmentMilestones
Namespace Prefix: | atxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of license fee payable related to related to regulatory approval and commercial sales milestones. + References No definition available. + Details
Name: | atxs_LicenseeFeePayableRegulatoryApprovalAndCommercialSalesMilestones
Namespace Prefix: | atxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of indications for license fee payable related to related to regulatory approval and commercial sales milestones. + References No definition available. + Details
Name: | atxs_LicenseeFeePayableRegulatoryApprovalAndCommercialSalesMilestonesMaximumNumberOfIndications
Namespace Prefix: | atxs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of upfront license fee paid. + References No definition available. + Details
Name: | atxs_PaymentOfUpfrontLicenseFees
Namespace Prefix: | atxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=atxs_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |